Femasys Inc. (NASDAQ:FEMY) Short Interest Up 70.1% in May

Femasys Inc. (NASDAQ:FEMY) saw a large growth in short interest in May. As of May 29th, there was short interest totaling 3,326,404 shares, a growth of 70.1% from the May 14th total of 1,955,435 shares. Based on an average daily trading volume, of 3,901,852 shares, the short-interest ratio is presently 0.9 days. Approximately 6.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of FEMY. Banco BTG Pactual S.A. bought a new position in Femasys in the 4th quarter valued at $88,000. Geode Capital Management LLC boosted its position in Femasys by 50.8% in the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after buying an additional 131,052 shares during the last quarter. Jane Street Group LLC bought a new position in Femasys in the 4th quarter valued at $62,000. Cetera Investment Advisers bought a new position in Femasys in the 4th quarter valued at $36,000. Finally, HRT Financial LP bought a new position in Femasys in the 4th quarter valued at $30,000. 65.27% of the stock is currently owned by institutional investors.

Femasys Stock Down 3.5%

Shares of FEMY traded down $0.14 during trading hours on Tuesday, hitting $3.84. 53,510 shares of the company were exchanged, compared to its average volume of 49,828. The company has a market cap of $11.60 million, a PE ratio of -0.71 and a beta of -2.23. The firm’s 50 day moving average is $7.51 and its 200-day moving average is $10.79. Femasys has a 52 week low of $3.77 and a 52 week high of $22.20. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Friday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $1.43. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.The company had revenue of $0.42 million during the quarter, compared to the consensus estimate of $0.77 million.

Wall Street Analyst Weigh In

FEMY has been the topic of a number of recent analyst reports. Lake Street Capital initiated coverage on Femasys in a research report on Tuesday, March 3rd. They set a “buy” rating and a $30.00 target price on the stock. Wall Street Zen upgraded Femasys to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 3rd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Femasys has a consensus rating of “Moderate Buy” and a consensus target price of $106.67.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.